Loading
Across 53 children treated with irinotecan, temozolomide and dinutuximab for relapsed neuroblastoma, four in ten had their tumours shrink and 85 percent were alive a year later, confirming the combination as the standard salvage treatment.
Report of the randomised and expansion cohorts of ANBL1221: 17 randomised and 36 non-randomly assigned patients received irinotecan, temozolomide, dinutuximab and GM-CSF.
Objective responses occurred in 52.9 percent of randomised and 36.1 percent of expansion patients, 41.5 percent overall, with stable disease in a further 22 of 53. One-year progression-free and overall survival were 67.9 and 84.9 percent. Fever and infection, neutropenia, pain and diarrhoea were the common grade 3 or higher toxicities; higher dinutuximab trough levels were associated with response.
Confirms irinotecan-temozolomide-dinutuximab as the reference salvage regimen and motivated frontline chemo-immunotherapy trials (ANBL17P1, ANBL1531).
Shares ANBL1221, Dinutuximab (ch14.18) / dinutuximab beta, High-risk neuroblastoma, Irinotecan (and liposomal irinotecan).
Shares ANBL1221, Dinutuximab (ch14.18) / dinutuximab beta, High-risk neuroblastoma, Neuroblastoma (paediatric).
Shares Dinutuximab (ch14.18) / dinutuximab beta, High-risk neuroblastoma, Temozolomide, Neuroblastoma (paediatric).
Shares Sargramostim, Dinutuximab (ch14.18) / dinutuximab beta, High-risk neuroblastoma, Neuroblastoma (paediatric).
Shares Dinutuximab (ch14.18) / dinutuximab beta, High-risk neuroblastoma, Neuroblastoma (paediatric).
Shares Sargramostim, Dinutuximab (ch14.18) / dinutuximab beta, Neuroblastoma (paediatric).
Shares Dinutuximab (ch14.18) / dinutuximab beta, High-risk neuroblastoma, Neuroblastoma (paediatric).
Shares Dinutuximab (ch14.18) / dinutuximab beta, High-risk neuroblastoma, Neuroblastoma (paediatric).